Applied BioCode (6598) — Cash Flow Reinvestment Rate

Latest as of September 2022: 2.85x

Applied BioCode (6598) has a Cash Flow Reinvestment Rate of 2.85x as of September 2022, reinvesting NT$18.11 Million (capex NT$12.00 Million plus investments NT$-6.11 Million) from operating cash flow of NT$6.35 Million. Check Applied BioCode cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

2.85x

(Capex + Investments) / Operating CF

Total Reinvested

NT$18.11 Million

Capex + Investments

Operating Cash Flow

NT$6.35 Million

TWD

Capital Expenditures

NT$12.00 Million

TWD

Applied BioCode Cash Flow Reinvestment Rate (2022–2022)

Historical reinvestment intensity for Applied BioCode across 1 annual periods. Explore Applied BioCode (6598) cash flow to debt to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Applied BioCode (2022–2022)

Year-by-year capital reinvestment analysis for Applied BioCode. For live market cap and broader valuation context, see Applied BioCode market cap and net worth.

Year	Reinvestment Rate	Total Reinvested (TWD)	Operating CF	Capex	YoY Change
2022	0.30x	NT$44.28 Million	NT$145.87 Million	NT$22.14 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow